Loft N, Egeberg A, Rasmussen MK, et al. - Researchers conducted this cohort study to evaluate the outcomes following a mandatory nonmedical switch from adalimumab originator to adalimumab biosimilars in patients with psoriasis. Between November 1, 2018, and May 1, 2019, all patients who switched from adalimumab originator to an adalimumab biosimilar were involved in the adalimumab biosimilar cohort. The adalimumab originator cohort included all patients who received adalimumab originator between May 1, 2017, and November 1, 2017. In total, 348 patients were involved in the adalimumab biosimilar cohort (mean [SD] age, 52.2 [13.6] years; 251 [72.1%] male) and 378 patients in the adalimumab originator cohort (mean [SD] age, 51.1 [14.1] years; 272 [72.0%] male). Data reported that the 1-year drug retention rates were 92.0% for the adalimumab biosimilar cohort and 92.1% for the adalimumab originator cohort. In this cohort study from Denmark, a nonmedical switch from adalimumab originator to adalimumab biosimilars was not related to drug retention.